Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

被引：4
|
作者：
Besse, Benjamin [1 ]
Garrido, Pilar [2 ]
Puente, Javier [3 ]
Cortot, Alexis [4 ]
Eugenia Olmedo, Maria [2 ]
Perol, Maurice [5 ]
Gil, Maciej [6 ]
Chao, Grace [7 ]
Shahidi, Javad [8 ]
Bennouna, Jaafar [9 ]
机构：
[1] Gustave Roussy, Dept Canc Med, Villejuif, France
[2] Hosp Univ Ramon Y Cajal, Med Oncol Dept, Madrid, Spain
[3] Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain
[4] Lille Univ Hosp, Thorac Oncol, Lille, France
[5] Ctr Leon Berard, Grp Thorac & Orl, Lyon, France
[6] Eli Lilly, Warsaw, Poland
[7] Eli Lilly & Co, Bridgewater, MA USA
[8] Eli Lilly & Co Bridgewater, Bridgewater, MA USA
[9] Inst Cancerol LOuest, Nantes, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
non-small cell lung cancer; Necitumumab; pembrolizumab;
D O I：
10.1016/j.jtho.2016.11.451
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA09.11
引用
收藏
页码：S397 / S397
页数：1
相关论文
共 50 条
  • [31] Definitive thoracic radiotherapy in oligometastatic stage IV non-small cell lung cancer (NSCLC).
    Fernandes, Annemarie Therese
    Xanthopoulos, Eric
    Handorf, Elizabeth
    Grover, Surbhi
    Sharma, Sonam
    Eaby-Sandy, Beth
    Evans, Tracey L.
    Stevenson, James
    Langer, Corey J.
    Mitra, Nandita
    Apisarnthanarax, Smith
    Lin, Lilie
    Rengan, Ramesh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study
    Dawson, A. G.
    Baines, C.
    Joshi, V.
    O'Byrne, K. J.
    Waller, D. A.
    LUNG CANCER, 2014, 83 : S78 - S78
  • [33] Clinicopathologic Characteristics And Predictors Of Survival In Stage Iv Non-Small Cell Lung Cancer (nsclc)
    Duma, N.
    Listo, M.
    Osorio, C.
    Zhang, S.
    Kang, M.
    Abu-Ihweij, K.
    Harper, H.
    Gutierrez, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [34] Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study
    Alan G Dawson
    Vijay Joshi
    David A Waller
    Journal of Cardiothoracic Surgery, 10 (Suppl 1)
  • [35] Serum autoantibodies as prognostic biomarkers for stage IV non-small cell lung cancer (NSCLC).
    Pergande, Melissa R.
    Piper, Clinton T.
    Fhied, Cristina L.
    Mahon, Brett
    Fidler, Mary J.
    Bonomi, Philip
    Borgia, Jeffrey Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Proton therapy for early-stage non-small cell lung cancer (NSCLC)
    Gomez, Daniel R.
    Li, Heng
    Chang, Joe Y.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (02) : 199 - 204
  • [37] Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study
    Saijo, N.
    Inagaki, Y.
    Abe, Y.
    Kono, S.
    Taniguchi, Y.
    Otsuka, K.
    Naoki, Y.
    Tamiya, A.
    Okishio, K.
    Atagi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S900 - S900
  • [38] Radiation therapy of stage I and II non-small cell lung cancer (NSCLC)
    Zierhut, D
    Bettscheider, C
    Schubert, K
    van Kampen, M
    Wannenmacher, M
    LUNG CANCER, 2001, 34 : S39 - S43
  • [39] The Efficacy and Safety of Nivolumab, Pembrolizumab, and Atezolizumab in Treatment of Advanced Non-small Cell Lung Cancer
    Chen, Rui
    Tao, Yuquan
    Xu, Xin
    Shan, Liang
    Jiang, Hongyuan
    Yin, Qilei
    Pei, Lingyan
    Cai, Feng
    Ma, Lifang
    Yu, Yongchun
    DISCOVERY MEDICINE, 2018, 26 (143) : 155 - 166
  • [40] Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
    Bar, J.
    Urban, D.
    Redinsky, I.
    Ackerstein, A.
    Daher, S.
    Kamer, I.
    Onn, A.
    Shulimzon, T.
    Peled, M.
    Zeitlin, N.
    Kremer, R.
    Raskin, S.
    Ben-Nun, A.
    Perelman, M.
    Ofek, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S865 - S866
12345